Organization (Nonprofit)
SRI International
ClinicalTrials.gov lists SRI International as lead sponsor of 10 trials. It has 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Unknown author Unknown author, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers SRI International: 10 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (20)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Obesity | 2 |
| Substance-Related Disorders | 2 |
| Alcoholism | 1 |
| Anthrax | 1 |
| Breast Neoplasms | 1 |
Showing 5 of 20 disease areas.
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2023 | 4 |
| 2021 | 2 |
| 2019 | 3 |
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 1 |
| 2013 | 1 |
| 2009 | 1 |
| 2008 | 1 |
Showing 10 of 12 years.
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (1)
| Drug | Trials |
|---|---|
| Varenicline | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 4 hit target (n=4) | 1 of 4 on time (n=4) |
Journals published in (20)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco | 3 |
| The Cochrane database of systematic reviews | 3 |
| BMC public health | 2 |
| Journal of substance abuse treatment | 2 |
| Annals of behavioral medicine : a publication of the Society of Behavioral Medicine | 1 |
Showing 5 of 20 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1,386 | 146 | 2025-12-23 |
Financing and grant events (141)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-30 | NIH grant | 75,224 | Reporter |
| 2025-09-30 | NIH grant | 13,910,251 | Reporter |
| 2025-09-30 | NIH grant | 830,604 | Reporter |
| 2025-09-30 | NIH grant | 714,077 | Reporter |
| 2025-09-30 | NIH grant | 214,778 | Reporter |
Showing 5 of 141 events.
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| SRI International | Menlo Park, US | FDA |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Institute of Tropical Medicine, Belgium | Co sponsors trial with | 1 |
| US Army Medical Research Institute of Infectious Diseases | Co sponsors trial with | 1 |
| Roham T. Zamanian | Co sponsors trial with | 1 |
Latest dated events (1,547)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-11-18 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 1,547 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| S R I INTERNATIONAL | Certificate of waiver | Active |
Biomarker capability evidence (27)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ESR1 | Trial sponsor | Named in trial inclusion criteria |
| PGR | Trial sponsor | Named in trial inclusion criteria |
| F2 | Trial sponsor | Named in trial exclusion criteria |
| F3 | Trial sponsor | Named in trial exclusion criteria |
| FXYD1 | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 27 evidence rows.
On Scientist.com
SRI International is listed as a research supplier in the Scientist.com network.
Service areas
SRI International Biosciences conducts basic research, drug discovery and development, and provides contract services for its clients and partners. SRI has the resources necessary to take R&D from "Idea to IND and Beyond"™ - from initial discovery, through GLP-compliant preclinical development, to human clinical trials. SRI specializes in cancer, immunology and inflammation, infectious disease, neuroscience, and metabolism. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology. SRI's clinical...
Show the full description
SRI International Biosciences conducts basic research, drug discovery and development, and provides contract services for its clients and partners. SRI has the resources necessary to take R&D from "Idea to IND and Beyond"™ - from initial discovery, through GLP-compliant preclinical development, to human clinical trials. SRI specializes in cancer, immunology and inflammation, infectious disease, neuroscience, and metabolism. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology. SRI's clinical development services include Phase I clinical trials and strategic development for young biotech and pharma companies.
Downloads:
Cell & Molecular Imaging Services - Immunohistochemistry, light and laser microscopy, morphology, membrane biology, and noninvasive imaging in rodents
Clinical Laboratory Services - hematology, clinical chemistry, coagulation, urinalysis, and biomarkers
Regulatory Support - preclinical development planning,pre-IND and IND support
Center for Infectious Disease and Biodefense - tropical disease research program, including anti-vector drug testing, anti-pathogen, cellular assays, and in situ analysis
Center for Neuroscience - neuroscience studies, including behavioral, in vivo, neurotransmitter, neurophysiology, and neuropharmacology
Pharmaceutical Sciences - preformulation studies, formulation development, alternative drug delivery, stability, dosage
Drug Discovery - target validation, assay development, lead identification, immunology, infectious diseases, oncology
Drug Metabolism, Pharmacokinetics, and Toxicology Services - Discovery ADMET, drug metabolism, safety pharmacology, genetic toxicology, and reproductive toxicology
- Website
- www.sri.com/research/biosciences
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, and biomarkers this organization publishes on.
Work with SRI Biosciences on Scientist.com
For prices, more details, or to contact SRI Biosciences, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.